Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

Health Care

Health Care

Group By Ticker
Sort By
Newest | Oldest
Read More
2 minute read
  • General
  • Health Care
  • Large Cap
  • Legal
  • News

Weedkiller Woes: Australian Court Nears Decision in Bayer’s Roundup Trial

By Vandana Singh
January 30, 8:49 AM
Follow the landmark Australian Roundup lawsuit against Bayer. Closing arguments in class action alleging Roundup's link to cancer.

BAYRY

Read More
2 minute read
  • Biotech
  • Financing
  • General
  • Health Care
  • Large Cap
  • Movers
  • News
  • Offerings
  • Trading Ideas

Pharma Giant Gilead Raises Stake In Cancer-Focused Arcus Biosciences, Stock Soars

By Vandana Singh
January 30, 7:27 AM
Arcus Biosciences sees a 17.1% surge as Gilead Sciences amends collaboration, investing $320M at $21.00/share. Accelerate joint programs in cancer therapy.

GILD

Read More
2 minute read
  • Equities
  • Health Care
  • Large Cap
  • Signals
  • Technicals
  • Top Stories
  • Trading Ideas

Investor Optimism Around Keytruda Drives Merck Stock To Golden Cross Ahead of Earnings

By Surbhi Jain
January 29, 3:05 PM
Merck stock has gained 20% since Nov. 28; a technical signal suggests the rally isn't over. Keytruda approvals also drive optimism.

HARP

Read More
2 minute read
  • Analyst Color
  • Analyst Ratings
  • Biotech
  • Equities
  • General
  • Health Care
  • Large Cap
  • News
  • Trading Ideas
  • Upgrades

AbbVie’s Transformational 2023, Analyst Anticipates Growth in 2024 Amid Competitive Pressures

By Vandana Singh
January 29, 3:04 PM
AbbVie's growth outlook in 2024 as William Blair upgrades, highlighting strong performance in Humira erosion management, strategic acquisitions, and a 3.8% dividend yield.

ABBV

Read More
2 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • Markets
  • News

Eli Lilly Wants to Expand Access to Weight-Loss Treatments In Germany, In Talks With Government

By Vandana Singh
January 29, 2:14 PM
Eli Lilly in talks with German government to lift ban on health system coverage for weight-loss treatments. Explore Mounjaro's recent EU approval and market launches.

LLY

Read More
1 minute read
  • Biotech
  • Contracts
  • General
  • Health Care
  • Large Cap
  • Movers
  • News
  • Trading Ideas

Roche Walks Away From HOOKIPA Pharma-Partnered KRAS-Focused Cancer Deal

By Vandana Singh
January 29, 1:55 PM
HOOKIPA Pharma's strategic focus on HB-200 program for HPV16+ HNSCC, infectious disease cure collaboration with Gilead, and recent developments.

GILD

Read More
2 minute read
  • Biotech
  • FDA
  • General
  • Health Care
  • Large Cap
  • News

Pfizer’s COVID-19 Treatment Paxlovid Will No Longer Be Available For Emergency Use After This Date, FDA Revises Label

By Vandana Singh
January 29, 1:39 PM
FDA revises emergency use authorization for Pfizer's Paxlovid, impacting distribution and treatment of mild-to-moderate COVID-19. Transitions from March 8.

PFE

Read More
2 minute read
  • Biotech
  • Equities
  • General
  • Health Care
  • Large Cap
  • News

Sarepta Therapeutics’ Next-Gen Duchenne Muscular Therapy Shows Efficacy At Less Frequent Dosing

By Vandana Singh
January 29, 12:48 PM
Sarepta Therapeutics unveils results from MOMENTUM study's Phase 2 trial for SRP-5051, a next-gen PPMO treatment targeting Duchenne muscular dystrophy.

SRPT

Read More
2 minute read
  • Biotech
  • Equities
  • General
  • Health Care
  • Movers
  • News
  • Trading Ideas

Why Is Gastrointestinal Disease-Focused Palisade Bio Stock Trading Higher Today?

By Vandana Singh
January 29, 11:15 AM
Palisade Bio' PALI-2108, a promising therapy for ulcerative colitis, shows impressive preclinical efficacy. PALI shares surge 151%.

PALI

Read More
2 minute read
  • General
  • Health Care
  • Legal
  • Media
  • News

Roundup Cancer Verdict: Woes Continue For Bayer As It Faces $2.2B Payout

By Vandana Singh
January 29, 10:41 AM
"Bayer's Monsanto ordered to pay $2.2 billion in Roundup cancer case. Explore the landmark verdict, compensatory losses, and punitive damages.

BAYRY

Posts pagination

Previous 1 … 68 69 70 … 478 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service